Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.
Several studies point to promising new approaches to treating and preventing Alzheimer’s disease and a deeper understanding of how the disease progresses.
Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
